Efficacy of resveratrol supplementation against non-alcoholic fatty liver disease: A meta-analysis of placebo-controlled clinical trials

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Zhang, Chongyang ^a   Yuan, Weigang ^a   Fang, Jianguo ^a   Wang, Wenqing ^a   He, Pei ^a   Lei, Jiahui ^a   Wang, Chunxu ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PLACEBO; RESVERATROL; LIPOPROTEIN; STILBENE DERIVATIVE;

ARTICLE; CHOLESTEROL BLOOD LEVEL; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; METABOLIC PARAMETERS; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT RESPONSE; BLOOD; FEMALE; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE;

CHOLESTEROL; FEMALE; HUMANS; LIPOPROTEINS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STILBENES;

EID: 84990050530     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0161792     Document Type: Article

References (33)

1. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013; 10: 686-690. doi: 10.1038/nrgastro.2013.171 PMID: 24042449
2. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of nonalcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011; 34: 274-285. doi: 10.1111/j.1365-2036.2011.04724.x PMID: 21623852
3. Marchesini G, Babini M. Nonalcoholic fatty liver disease and the metabolic syndrome. Minerva Cardioangiol. 2006; 54: 229-239. PMID: 16778754
4. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010; 52: 1836-1846. doi: 10.1002/hep.24001 PMID: 21038418
5. Lonardo A, Sookoian S, Chonchol M, Loria P, Targher G. Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des. 2013; 19: 5177-5192. PMID: 23432668
6. Dudekula A, Rachakonda V, Shaik B, Behari J. Weight loss in nonalcoholic Fatty liver disease patients in an ambulatory care setting is largely unsuccessful but correlates with frequency of clinic visits. PloS One. 2014; 9: e111808. doi: 10.1371/journal.pone.0111808 PMID: 25375228
7. Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y, et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Dig Liver Dis. 2015; 47: 226-232. doi: 10.1016/j.dld.2014.11.015 PMID: 25577300
8. Nagao K, Inoue N, Inafuku M, Shirouchi B, Morooka T, Nomura S, et al. Mukitake mushroom (Panellus serotinus) alleviates nonalcoholic fatty liver disease through the suppression of monocyte chemoattractant protein 1 production in db/db mice. J Nutr Biochem. 2010; 21: 418-423. doi: 10.1016/j.jnutbio.2009.01.021 PMID: 19423319
9. Salamone F, Galvano F, Marino Gammazza A, Paternostro C, Tibullo D, Bucchieri F, et al. Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis. Dig Liver Dis. 2012; 44: 334-342. doi: 10.1016/j.dld.2011.11.010 PMID: 22197629
10. Salamone F, Galvano F, Cappello F, Mangiameli A, Barbagallo I, Li Volti G. Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Transl Res. 2012; 159: 477-486. doi: 10.1016/j.trsl.2011.12.003 PMID: 22633099
11. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006; 444: 337-342. PMID: 17086191
12. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006; 5: 493-506. PMID: 16732220
13. Hung LM, Chen JK, Huang SS, Lee RS, Su MJ. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc Res. 2000; 47: 549-555. PMID: 10963727
14. Das S, Das DK. Resveratrol: a therapeutic promise for cardiovascular diseases. Recent Pat Cardiovasc Drug Discov. 2007; 2: 133-138. PMID: 18221111
15. Das S, Das DK. Anti-inflammatory responses of resveratrol. Inflamm Allergy Drug Targets. 2007; 6: 168-173. PMID: 17897053
16. Schmatz R, Perreira LB, Stefanello N, Mazzanti C, Spanevello R, Gutierres J, et al. Effects of resveratrol on biomarkers of oxidative stress and on the activity of delta aminolevulinic acid dehydratase in liver and kidney of streptozotocin-induced diabetic rats. Biochimie. 2012; 94: 374-383. doi: 10.1016/j.biochi.2011.08.005 PMID: 21864646
17. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006; 127: 1109-1122. PMID: 17112576
18. Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes. 2010; 59: 554-563. doi: 10.2337/db09-0482 PMID: 19934007
19. Tennen RI, Michishita-Kioi E, Chua KF. Finding a target for resveratrol. Cell. 2012; 148: 387-389. doi: 10.1016/j.cell.2012.01.032 PMID: 22304906
20. Andrade JM, Paraiso AF, de Oliveira MV, Martins AM, Neto JF, Guimaraes AL, et al. Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition. 2014; 30: 915-919. doi: 10.1016/j.nut.2013.11.016 PMID: 24985011
21. Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014; 12: 2092-2103 e1-6. doi: 10.1016/j.cgh.2014.02.024 PMID: 24582567
22. Heebøll S, Kreuzfeldt M, Hamilton-Dutoit S, Kjær Poulsen M, Stødkilde-Jørgensen H, Møller HJ, et al. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol. 2016; 51: 456-464. doi: 10.3109/00365521.2015.1107620 PMID: 26784973
23. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6: e1000100. doi: 10.1371/journal.pmed.1000100 PMID: 19621070
24. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22: 719-748. PMID: 13655060
25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-188. PMID: 3802833
26. Faghihzadeh F, Adibi P, Hekmatdoost A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2015; 114: 796-803. doi: 10.1017/S0007114515002433 PMID: 26234526
27. Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014; 34: 837-843. doi: 10.1016/j.nutres.2014.09.005 PMID: 25311610
28. Popov VB, Lim JK. Treatment of nonalcoholic fatty liver disease: the role of medical, surgical, and endoscopic weight loss. J Clin Transl Hepatol. 2015; 3: 230-238. doi: 10.14218/JCTH.2015.00019 PMID: 26623270
29. Qiu LX, Chen T. Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease. World J Gastroenterol. 2015; 21: 1099-1107. doi: 10.3748/wjg.v21.i4.1099 PMID: 25632182
30. Wang ZQ, Zhang XH, Yu Y, Tipton RC, Raskin I, Ribnicky D, et al. Artemisia scoparia extract attenuates non-alcoholic fatty liver disease in diet-induced obesity mice by enhancing hepatic insulin and AMPK signaling independently of FGF21 pathway. Metabolism. 2013; 62: 1239-1249. doi: 10.1016/j.metabol.2013.03.004 PMID: 23702383
31. Li L, Hai J, Li Z, Zhang Y, Peng H, Li K, et al. Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol. 2014; 63: 166-173. doi: 10.1016/j.fct.2013.08.036 PMID: 23978414
32. Bo S, Ciccone G, Castiglione A, Gambino R, De Michieli F, Villois P, et al. Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, crossover trial. Curr Med Chem. 2013; 20: 1323-1331. PMID: 23298135
33. Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stødkilde-Jørgensen H, et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 2013; 62: 1186-1195. doi: 10.2337/db12-0975 PMID: 23193181